Moore KT - Search Results

1

Clinical research vehicles as a modality for medical research education and conduct of decentralized trials, supporting justice, equity, and diversity in research.

Moore KT. Moore KT. Bioethics. 2025 Feb;39(2):213-220. doi: 10.1111/bioe.13360. Epub 2024 Oct 3. Bioethics. 2025. PMID: 39360374

2

The Importance of Participant Tracking When Conducting Clinical Pharmacology Drug Trials.

Moore KT, Fossler MJ Jr, Younis I; ACCP Public Policy Committee. Moore KT, et al. J Clin Pharmacol. 2022 Dec;62(12):1465-1467. doi: 10.1002/jcph.2135. Epub 2022 Sep 22. J Clin Pharmacol. 2022. PMID: 36031876 No abstract available.

3

The Importance of Assessing Drug Pharmacokinetics and Pharmacodynamics in the Obese Population During Drug Development.

Moore KT, Zannikos PN, Masters JC, Willmann S, Shen J, Frost C. Moore KT, et al. J Clin Pharmacol. 2023 Nov;63 Suppl 2:S78-S84. doi: 10.1002/jcph.2361. J Clin Pharmacol. 2023. PMID: 37942912

4

Drug Lawsuit Advertisements and the Importance of Physician Consultation Prior to Voluntary Medication Withdrawal or Transition.

Moore KT, Pai SM, Rogge M; ACCP Public Policy Committee. Moore KT, et al. J Clin Pharmacol. 2022 Dec;62(12):1468-1471. doi: 10.1002/jcph.2136. Epub 2022 Sep 22. J Clin Pharmacol. 2022. PMID: 35994373 No abstract available.

5

American Geriatrics Society Beers Criteria and Anticoagulant Use in Older Adults With Renal Impairment.

Foody J, Moore KT. Foody J, et al. Among authors: moore kt. Kidney Int Rep. 2017 Dec 5;3(1):222-223. doi: 10.1016/j.ekir.2017.11.006. eCollection 2018 Jan. Kidney Int Rep. 2017. PMID: 29340340 Free PMC article. No abstract available.

6

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations.

Ashton V, Kerolus-Georgi S, Moore KT. Ashton V, et al. Among authors: moore kt. J Clin Pharmacol. 2021 Aug;61(8):1010-1026. doi: 10.1002/jcph.1838. Epub 2021 Mar 13. J Clin Pharmacol. 2021. PMID: 33599985 Free PMC article. Review.

7

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations.

Ashton V, Mudarris L, Moore KT. Ashton V, et al. Among authors: moore kt. Am J Cardiovasc Drugs. 2021 May;21(3):283-297. doi: 10.1007/s40256-020-00434-w. Am J Cardiovasc Drugs. 2021. PMID: 32803514 Free PMC article. Review.

8

Bioequivalence and safety of a novel fentanyl transdermal matrix system compared with a transdermal reservoir system.

Moore KT, Adams HD, Natarajan J, Ariyawansa J, Richards HM. Moore KT, et al. J Opioid Manag. 2011 Mar-Apr;7(2):99-107. doi: 10.5055/jom.2011.0052. J Opioid Manag. 2011. PMID: 21561033 Clinical Trial.

9

Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban.

Moore KT, Wong P, Zhang L, Pan G, Foody J. Moore KT, et al. Curr Med Res Opin. 2018 Dec;34(12):2053-2061. doi: 10.1080/03007995.2018.1492374. Epub 2018 Aug 5. Curr Med Res Opin. 2018. PMID: 29932775 Review.

10

Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease.

Volkl AA, Moore KT, Haskell L, Barnathan ES. Volkl AA, et al. Among authors: moore kt. Am J Cardiovasc Drugs. 2023 May;23(3):247-255. doi: 10.1007/s40256-023-00579-4. Epub 2023 Apr 28. Am J Cardiovasc Drugs. 2023. PMID: 37115488 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters